Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In Vivo Pharmacodynamic Activity of the Glycopeptide Dalbavancin

17 Feb 2007

Abstract excerpt

Dalbavancin is a lipoglycopeptide antibiotic with broad-spectrum activity against gram-positive cocci and a markedly prolonged serum elimination half-life. We used the neutropenic murine thigh and lung infection models to characterize the pharmacodynamics of dalbavancin. Single-dose pharmacokinetic studies demonstrated linear kinetics and a prolonged elimination half-life which ranged from 7.6 to 13.1 h over the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibiotics Pharmacokinetics and Efficacy
Share to Antimicrobial Resistance in Staphylococcus
Share to Pneumonia and Respiratory Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 17307987
DOI: 10.1128/aac.01264-06

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In Vivo Pharmacodynamic Activity of the Glycopeptide DalbavancinPMID 17307987Read ↗

In Vivo Pharmacodynamic Activities of Two Glycylcyclines (GAR-936 and WAY 152,288) against Various Gram-Positive and Gram-Negative BacteriaSemantic proximity Read ↗

Bactericidal Activity and Resistance Development Profiling of DalbavancinSemantic proximity Read ↗

Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.Semantic proximity Read ↗

In vivopharmacodynamics of new-generation β-lactamase inhibitor taniborbactam (formerly VNRX-5133) in combination with cefepime against serine-β-lactamase-producing Gram-negative bacteriaSemantic proximity Read ↗

Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to HumansSemantic proximity Read ↗

Off-label use of dalbavancin in children: a case seriesSemantic proximity Read ↗

Daptomycin Dose-Effect Relationship against Resistant Gram-Positive OrganismsSemantic proximity Read ↗

In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agentsSemantic proximity Read ↗

I n vitro pharmacokinetics/pharmacodynamics of the β-lactamase inhibitor, durlobactam, in combination with sulbactam against Acinetobacter baumannii-calcoaceticus complexSemantic proximity Read ↗

Cost-Utility of Dalbavancin as a Treatment Option for Adult Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in CanadaSemantic proximity Read ↗

In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.Semantic proximity Read ↗

Efficacy of Humanized Exposures of Cefiderocol (S-649266) against a Diverse Population of Gram-Negative Bacteria in a Murine Thigh Infection ModelSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.